Anthem Biosciences Limited (NSE:ANTHEM)
India · Delayed Price · Currency is INR 652.35
+9.55 (1.49%)
Jan 7, 2026, 11:50 AM IST
Anthem Biosciences Revenue
Anthem Biosciences had revenue of 5.50B INR in the quarter ending September 30, 2025, with 4.78% growth. This brings the company's revenue in the last twelve months to 20.77B, up 22.34% year-over-year. In the fiscal year ending March 31, 2025, Anthem Biosciences had annual revenue of 18.50B with 30.29% growth.
Revenue (ttm)
20.77B
Revenue Growth
+22.34%
P/S Ratio
17.38
Revenue / Employee
10.58M
Employees
1,825
Market Cap
361.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 18.50B | 4.30B | 30.29% |
| Mar 31, 2024 | 14.20B | 3.62B | 34.24% |
| Mar 31, 2023 | 10.58B | -1.83B | -14.74% |
| Mar 31, 2022 | 12.41B | 1.35B | 12.24% |
| Mar 31, 2021 | 11.05B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Glenmark Pharmaceuticals | 159.97B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |